1. Safety of a second homologous Ad26.COV2.S vaccine among healthcare workers in the phase 3b implementation Sisonke study in South Africa.
- Author
-
Takalani, Azwidihwi, Robinson, Michelle, Jonas, Phumeza, Bodenstein, Annie, Sambo, Vuyelo, Jacobson, Barry, Louw, Vernon, Opie, Jessica, Peter, Jonny, Rowji, Pradeep, Seocharan, Ishen, Reddy, Tarylee, Yende-Zuma, Nonhlanhla, Khutho, Kentse, Sanne, Ian, Bekker, Linda-Gail, Gray, Glenda, Garrett, Nigel, and Goga, Ameena
- Subjects
- *
MEDICAL personnel , *PORTAL vein , *THROMBOEMBOLISM , *THROMBOSIS , *VACCINES , *VACCINE safety - Abstract
The Sisonke 2 study provided a homologous boost at least 6 months after administration of the priming dose of Ad26.COV2.S for healthcare workers enrolled on the Sisonke phase 3b implementation study. Safety monitoring was via five reporting sources: (i.) self-report through a web-link; (ii.) paper-based case report forms; (iii.) a toll-free telephonic reporting line; (iv.) healthcare professionals-initiated reports; and (v.) active linkage with National Disease Databases. A total of 2350 adverse events were reported by 2117 of the 240 888 (0.88%) participants enrolled; 1625 of the 2350 reported events are reactogenicity events and 28 adverse events met seriousness criteria. No cases of thrombosis with thrombocytopaenia syndrome were reported; all adverse events including thromboembolic disorders occurred at a rate below the expected population rates apart from one case of Guillain Barre Syndrome and one case of portal vein thrombosis. The Sisonke 2 study demonstrates that two doses of Ad26.COV2.S is safe and well tolerated; and provides a feasible model for national pharmacovigilance strategies for low- and middle-income settings. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF